497 related articles for article (PubMed ID: 33556453)
1. DNA damage response inhibitors: An avenue for TNBC treatment.
Jin J; Tao Z; Cao J; Li T; Hu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
[TBL] [Abstract][Full Text] [Related]
2. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
3. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
Ha DH; Min A; Kim S; Jang H; Kim SH; Kim HJ; Ryu HS; Ku JL; Lee KH; Im SA
Sci Rep; 2020 Jun; 10(1):9930. PubMed ID: 32555285
[TBL] [Abstract][Full Text] [Related]
6. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
Shi Y; Jin J; Wang X; Ji W; Guan X
Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of DNA Damage Response in Cancer.
Choi W; Lee ES
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
[TBL] [Abstract][Full Text] [Related]
8. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
9. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
10. [Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].
Wang X; Yue J; Kang YK; Gao SL; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):787-795. PubMed ID: 37805443
[No Abstract] [Full Text] [Related]
11. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
12. Breaking the DNA damage response to improve cervical cancer treatment.
Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
[TBL] [Abstract][Full Text] [Related]
13. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic landscape in mutational triple negative breast cancer.
Shi Y; Jin J; Ji W; Guan X
Mol Cancer; 2018 Jul; 17(1):99. PubMed ID: 30007403
[TBL] [Abstract][Full Text] [Related]
16. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.
Sofianidi A; Dumbrava EE; Syrigos KN; Nasrazadani A
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539474
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
18. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
19. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
20. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]